starbuxsux Tuesday, 02/04/20 11:19:52 AM Re: deadjim post# 2354 Post # of 2370 LJPC Mar 20 '20 $4 Call LA JOLLA PHARMACEUTICAL CO still holding one for earnings on Feb 4 Two Small Biotechs See Big Stock Purchases by Their Largest Holders -- Barrons.com 6:59 AM ET 1/15/20 | Dow Jones Quote: On Monday, investment firm Tang Capital Management disclosed that it had paid $17.4 million from Jan. 9-13 for 2.97 million additional shares of La Jolla, an average per-share price of $5.87, according to a form it filed with the Securities and Exchange Commission. It now owns 7.9 million La Jolla shares. Tang Capital's president, Kevin Tang, is also chairman of La Jolla. Including the 310,000 La Jolla shares that Kevin Tang personally owns, his 8.2 million shares represent a 30.2% stake in La Jolla. These purchases of La Jolla stock are Tang Capital's first since last January, when it paid $7 million for 1.2 million shares, an average per-share price of $5.37 each. La Jolla Pharm reports prelim Q4 GIAPREZA net sales were $7.2 million, up 71% from the three months ended December 31, 2018 8:01 AM ET 1/9/20 | Briefing.com Quote: Vials of GIAPREZA shipped from distributors to hospitals (hospital demand) grew 74% for the three months ended December 31, 2019 as compared to the three months ended December 31, 2018 and 18% as compared to the three months ended September 30, 2019. For the twelve months ended December 31, 2019, preliminary GIAPREZA net sales were $23.1 million, up 129% from the twelve months ended December 31, 2018. La Jolla announced the commercial availability of GIAPREZA in the U.S. in March 2018.